摘要
目的系统评价香砂六君子汤加减治疗慢性萎缩性胃炎(CAG)的疗效和安全性。方法计算机检索Cochrane图书馆、PubMed、Medline、CBM、CINK、VIP和万方数据库等,纳入香砂六君子汤加减与其他药物治疗慢性萎缩性胃炎的随机对照试验(RCT),所有检索均截至2012-09-31。两名评价者分别独立提取资料、进行方法学质量评价和分析。结果共纳入8个RCT,研究质量不高。Meta分析结果显示:共有8个研究报道总有效率,结果显示香砂六君子汤加减治疗萎缩性胃炎总有效率优于其他常规治疗,两组比较差异有统计学意义[n=8,RR=1.16,95%CI(1.07,1.25),P<0.000 01]。8项试验中,2项试验对不良反应进行了描述,均提到无明显不良反应。结论香砂六君子汤加减治疗CAG疗效较一般中成药和西药好,但鉴于本研究纳入的原始文献质量不高,有效性和安全性尚不能得肯定结论,开展更多大样本、多中心、方法科学和规范的高质量的随机时照试验非常必要。
Objective To assess the effectiveness and safety of Xiangsha Liujunzi decoction for chronic atrophic gastritis. Methods The randomized controlled trials （RCTs） of Xiangsha Liujunzi decoction for chronic atrophic gastritis compared with other medicines were collected by searching The Cochrane Library, EMbase, PubMed, CBM, CNK, VIP and Wanfang databases. All the trials were before 2011.12.30, and a critical quality assessment and Meta - analysis were performed independently for the included studies. Results 8 trials were included, and the qualities were low. Compared with the control group, Xiangsha Liujunzi decoction group had superiority in remission rate based on clinical symptoms [ n = 8, RR = 1. 16,95% CI （ 1.07,1.25 ）, P 〈 0. 00001 ]. 2 RCTs were found to describe the safety of Xiangsha Liujunzi decoction for CAG. Conclusion Because of low quality, there was no enough evidence on Xiangsha Liujunzi decoction for CAG, So more high -quality multi -center RCTs in large scale are required.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2013年第11期2613-2616,共4页
Lishizhen Medicine and Materia Medica Research
基金
国家中医临床研究基地"龙医团队"科研项目(No.LYTD-13)"
关键词
香砂六君子汤
慢性萎缩性胃炎
系统评价
META分析
Xiangsha Liujunzi decoction
Chronic atrophic gastritis
Systematic review
Meta - analysis
